Deprescribing for older people living in residential aged care facilities: Pharmacist recommendations, doctor acceptance and implementation

Hui Wen Quek(The University of Western Australia), Kathleen N. Potter(University of Southampton), Vasi Naganathan(The University of Sydney), Christopher Etherton‐Beer(The University of Western Australia), Sarah N. Hilmer(Northern Sydney Local Health District), Andrew J. McLachlan(The University of Sydney), Tracy Comans(Queensland University of Technology), Richard I. Lindley(Westmead Hospital), Leanne Kearney(Concord Repatriation General Hospital), Amy Page(The University of Western Australia), Sarita Lo(The University of Sydney)
Archives of Gerontology and Geriatrics
December 19, 2022
10.1016/j.archger.2022.104910
Cited by 31

Related Papers

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
|The Lancet|2014|2.7k
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
|The Lancet|2012|1.2k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
|The Lancet|2012|1k